James Gruber
Director of Finance/CFO bei ETON PHARMACEUTICALS, INC.
Vermögen: 13 496 $ am 31.03.2024
Profil
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. He previously worked as the Vice President & Controller at Horizon Therapeutics, Inc. Gruber received an undergraduate degree from Indiana University and an MBA from Kellogg School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.02.2024 | 3 599 ( 0,01% ) | 13 496 $ | 31.03.2024 |
Aktive Positionen von James Gruber
| Unternehmen | Position | Beginn |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Director of Finance/CFO | 11.04.2022 |
Ehemalige bekannte Positionen von James Gruber
| Unternehmen | Position | Ende |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Ausbildung von James Gruber
| Indiana University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
